Dishman Carbogen Amcis Ltd is Rated Hold

Current Rating and Its Significance

MarketsMOJO’s 'Hold' rating for Dishman Carbogen Amcis Ltd indicates a neutral stance on the stock, suggesting that investors should neither aggressively buy nor sell at this juncture. This rating reflects a balanced view where the company exhibits certain strengths but also faces challenges that temper enthusiasm. The rating was revised from 'Sell' to 'Hold' on 05 January 2026, accompanied by a 10-point increase in the Mojo Score, now standing at 53.0. This score positions the stock in the mid-range of the rating spectrum, signalling moderate confidence in its near-term prospects.

Here’s How the Stock Looks Today

As of 10 January 2026, Dishman Carbogen Amcis Ltd is classified as a small-cap company operating within the Pharmaceuticals & Biotechnology sector. The stock has experienced mixed returns over various time frames: a modest decline of 0.54% on the day, a 1.04% gain over the past week, and a notable 15.25% rise in the last month. However, longer-term returns have been less favourable, with a 6.61% loss over the past year. Despite this, the company’s profitability has improved significantly, with profits rising by 191.6% over the same period, underscoring a divergence between market sentiment and operational performance.

Quality Assessment

The quality grade for Dishman Carbogen Amcis Ltd is rated below average, reflecting some structural weaknesses in its business fundamentals. The company’s long-term fundamental strength is relatively weak, with an average Return on Capital Employed (ROCE) of just 0.97%. This low ROCE indicates limited efficiency in generating returns from its capital base. Additionally, net sales have grown at a modest compound annual growth rate of 6.99% over the past five years, suggesting moderate top-line expansion. The company’s debt servicing capacity is also a concern, with a high Debt to EBITDA ratio of 4.96 times, signalling elevated leverage and potential financial risk.

Valuation Perspective

Valuation is a key factor supporting the 'Hold' rating, with the company’s valuation grade assessed as very attractive. The stock trades at a discount relative to its peers, with an Enterprise Value to Capital Employed ratio of 0.7, which is considered low and indicative of undervaluation. The ROCE has improved to 3.2%, which, while still modest, supports the valuation appeal. The company’s PEG ratio stands at 0.1, highlighting that earnings growth is not fully priced into the stock. This valuation attractiveness offers a cushion for investors, suggesting limited downside risk from current levels.

Financial Trend and Profitability

Financially, the company shows positive trends, earning a positive financial grade. Dishman Carbogen Amcis Ltd has reported positive results for the last three consecutive quarters, with operating profit to net sales reaching a quarterly high of 22.81%. The latest quarterly profit after tax (PAT) was ₹65.27 crores, and earnings per share (EPS) stood at ₹4.16, both representing the highest levels recorded recently. These figures indicate improving operational efficiency and profitability, which are encouraging signs for investors seeking stability and growth potential.

Technical Outlook

From a technical standpoint, the stock is mildly bearish, reflecting some caution in price momentum and market sentiment. While short-term price movements have shown some gains, the three-month return is negative at -9.05%, and the six-month return is nearly flat at -0.23%. This technical grade suggests that the stock may face resistance in breaking out to higher levels in the near term, warranting a cautious approach for traders and investors relying on technical signals.

Institutional Investor Activity

Another factor influencing the rating is the declining participation of institutional investors. Over the previous quarter, institutional holdings decreased by 1.76%, with these investors now collectively holding 9.44% of the company’s shares. Institutional investors typically possess greater analytical resources and market insight, so their reduced stake may reflect concerns about the company’s near-term prospects or sector dynamics. This trend adds a layer of caution for retail investors considering the stock.

Implications for Investors

For investors, the 'Hold' rating on Dishman Carbogen Amcis Ltd suggests a wait-and-watch approach. The company’s very attractive valuation and improving financial trends provide a foundation for potential upside, but the below-average quality metrics and mild technical weakness advise caution. Investors should monitor the company’s ability to sustain profit growth and manage its debt levels effectively. Additionally, watching institutional investor activity may offer clues about market confidence in the stock’s future trajectory.

Sector and Market Context

Operating within the Pharmaceuticals & Biotechnology sector, Dishman Carbogen Amcis Ltd faces competitive pressures and regulatory challenges typical of the industry. The sector often rewards companies with strong innovation pipelines and robust financial health. While Dishman Carbogen Amcis Ltd’s recent profit growth is promising, its modest sales growth and leverage issues highlight areas requiring improvement to compete effectively. The stock’s performance relative to sector peers and broader market indices should be considered when making investment decisions.

Summary

In summary, Dishman Carbogen Amcis Ltd’s current 'Hold' rating by MarketsMOJO, updated on 05 January 2026, reflects a balanced view of the company’s prospects as of 10 January 2026. The stock offers value through attractive valuation and improving profitability but is tempered by below-average quality and cautious technical signals. Investors should weigh these factors carefully and consider their risk tolerance and investment horizon before taking a position.

Key Metrics at a Glance (As of 10 January 2026)

• Mojo Score: 53.0 (Hold)


• Market Capitalisation: Small Cap


• Return on Capital Employed (ROCE): 3.2%


• Debt to EBITDA Ratio: 4.96 times


• Operating Profit to Net Sales (Quarterly): 22.81%


• Profit After Tax (Quarterly): ₹65.27 crores


• Earnings Per Share (Quarterly): ₹4.16


• 1-Year Stock Return: -6.61%


• Profit Growth (1 Year): +191.6%


• PEG Ratio: 0.1


• Institutional Holding: 9.44% (down 1.76% last quarter)

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →